English  |  正體中文  |  简体中文  |  Total items :0  
Visitors :  52676402    Online Users :  571
Project Commissioned by the Ministry of Education
Project Executed by National Taiwan University Library
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
About TAIR

Browse By

News

Copyright

Related Links

"yau t"

Return to Browse by Author
Sorting by Title Sort by Date

Showing items 1-25 of 43  (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page

Institution Date Title Author
國立成功大學 2023 Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results from a Randomized, Open-Label, Phase III Trial Tempero, M.A.;Pelzer, U.;O'Reilly, E.M.;Winter, J.;Oh, D.-Y.;Li, C.-P.;Tortora, G.;Chang, H.-M.;Lopez, C.D.;Bekaii-Saab, T.;Ko, A.H.;Santoro, A.;Park, J.O.;Noel, M.S.;Frassineti, G.L.;Shan, Y.-S.;Dean, A.;Riess, H.;Van, Cutsem E.;Berlin, J.;Philip, Philip P.;Moore, Moore M.;Goldstein, D.;Tabernero, J.;Li, M.;Ferrara, S.;Le, Bruchec Y.;Zhang, G.;Lu, B.;Biankin, A.V.;Reni, M.;Epstein, R.;Vasey, P.;Shapiro, J.;Burge, M.;Chua, Y.J.;Harris, M.;Pavlakis, N.;Tebbutt, N.;Prager, G.;Dittrich, C.;L�ngle, F.;Philipp-Abbrederis, K.;Greil, R.;St�ger, H.;Girschikofsky, M.;Kuehr, T.;Van, Laethem J.-L.;Laurent, S.;Dhani, N.;Ko, Y.J.;Dowden, S.;Kavan, P.;Tehfe, M.�.;Kubala, E.;Kohoutek, M.;Pfeiffer, Pfeiffer P.;Yilmaz, M.;Parner, V.;Salminen, T.;Soveri, L.-M.;Korkeila, E.;Osterlund, P.;Taieb, J.;Tougeron, D.;Artru, P.;Caroli-Bosc, F.X.;Guimbaud, R.;Turpin, A.;Walter, T.;Bachet, J.B.;Kunzmann, V.;Kreth, F.;Block, A.;Venerito, M.;Oettle, H.;Karthaus, M.;Trojan, J.;Folprecht, G.;Lerch, M.;Kullmann, F.;Reiser, M.;Heinemann, V.;W�rns, M.-A.;Schulz, H.;Garlipp, B.;Yau, T.;Chan, L.S.;Juhasz, B.;Landherr, Landherr L.;Pinter, T.;Bodoky, G.;Kah�n, Z.;McDermott, R.;Power, D.;Gianni, L.;Siena, Siena S.;Milella, Milella M.;Falcone, A.;Berardi, R.;Bagal�, C.;Di, Costanzo F.;Roila, F.;Ardizzoni, Ardizzoni A.;Maiello, E.;Fanello, S.;Wilmink, J.;Willem, De Groot J.;Creemers, G.;Barroso, E.;Rodrigues, T.;Sarmento, C.;Chee, Chee C.E.;Tai, D.;Mercade, T.M.;Medina, Medina M.H.;Mena, A.C.;Santasusana, J.M.;Flor, Oncala M.J.;Martin, C.G.;Lopez, R.;Mu�oz, A.;Garcia, R.V.;Ales, I.;S�ez, B.L.;Rivera, F.;Sastre, J.;Wu, C.-C.;Tien, Y.-W.;Chan, D.-C.;Hwang, T.-L.;Evans, J.;Wadsley, J.;Corrie, P.;Biankin, A.;Ko, A.;Cardin, D.;Chiorean, E.;Bendell, J.;Noonan, A.;Kindler, H.;Fernando, N.;Beg, M.;George, T.;Noel, M.;Loconte, N.;Arena, F.;Posey, J.;Malhotra, R.;Lopez, C.;Sohal, D.;McWilliams, R.;Brenner, W.;Womack, M.;Seth, R.;Lyer, R.;Bahary, N.;Marsh, R.;Ramirez, Ramirez R.;Chua, Chua C.;Reeves, J.;Manji, G.;El-Khoueiry, A.;Weaver, R.;Sahai, V.;Messersmith, W.;Dreicer, R.;Zakari, A.;Bullock, A.;Musher, B.;Borad, M.;Kim, E.;Bajor, D.;Huyck, T.;Hatoum, Hatoum H.;Xiong, H.;Pasche, B.;Lacy, J.;Olowokure, Olowokure O.;Cohn, A.;Richards, D.;Martin, R.;Paulson, A.;Fanta, P.;Krishnamurthi, S.;Oberstein, P.;Fuloria, J.
國家衛生研究院 2022-09 Systemic treatment of advanced unresectable hepatocellular carcinoma after first-line therapy: Expert recommendations from Hong Kong, Singapore, and Taiwan Yau, T;Tai, D;Chan, SL;Huang, YH;Choo, SP;Hsu, C;Cheung, TT;Lin, SM;Yong, WP;Lee, J;Leung, T;Shum, T;Yeung, CSY;Tai, AY;Law, ALY;Cheng, AL;Chen, LT
臺大學術典藏 2022-08-19T06:48:43Z Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma Wang Y.; Burgoyne A.M.; Dayyani F.; Spahn J.; Verret W.; Finn R.S.; Toh H.C.; Lujambio A.; Yau T.; Kaseb A.O.; Ryoo B.-Y.; He A.R.; CHIH-HUNG HSU; Zhang W.; Koeppen H.; Lu S.; Guan Y.; de Galarreta M.R.; Abbas A.R.; Zhu A.X.
臺大學術典藏 2022-08-19T00:20:37Z Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis Kuromatsu R.; Moriguchi M.; Chao Y.; Zhao H.; Anderson J.; Cruz C.D.; Kudo M.; Ikeda M.; Chopra A.; Numata K.; Yeo W.; Kang Y.-K.; Hou M.-M.; Kim T.-Y.; Choo S.-P.; CHIUN HSU; Yau T.
臺大學術典藏 2022-08-19T00:20:36Z Corrigendum to ��Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis�� [J Hepatol 71 (2019) 543�V552](S0168827819303009)(10.1016/j.jhep.2019.05.014) Kudo M.; Dela Cruz C.; Anderson J.; Zhao H.; Chao Y.; Moriguchi M.; Kuromatsu R.; Ikeda M.; Yeo W.; Chopra A.; Yau T.; CHIUN HSU; Kim T.-Y.; Choo S.-P.; Kang Y.-K.; Hou M.-M.; Numata K.
臺大學術典藏 2022-08-19T00:20:32Z Novel systemic therapy for hepatocellular carcinoma Dong Y.; Liu T.-H.; Yau T.; CHIUN HSU
臺大學術典藏 2022-06-10T06:10:59Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏 2022-06-10T06:10:56Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏 2022-03-10T06:14:59Z Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens Dai M.S.; Feng Y.H.; Chen S.W.; Masuda N.; Yau T.; Chen S.T.; YEN-SHEN LU; Yap Y.S.; Ang P.C.S.; Chu S.C.; Kwong A.; Lee K.S.; Ow S.; Kim S.B.; Lin J.; Chung H.C.; Ngan R.; Kok V.C.; Rau K.M.; Sangai T.; Ng T.Y.; Tseng L.M.; Bryce R.; Bebchuk J.; Chen M.C.; Hou M.F.
臺大學術典藏 2022-02-21T02:04:35Z Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study Qin S.; Ren Z.; Feng Y.-H.; Yau T.; Wang B.; Zhao H.; Bai Y.; Gu S.; Li L.; Hernandez S.; Xu D.-Z.; Mulla S.; Wang Y.; Shao H.; ANN-LII CHENG
臺大學術典藏 2022-02-21T02:04:35Z Pembrolizumab as second-line therapy for advanced hepatocellular carcinoma: A subgroup analysis of asian patients in the phase 3 KEYNOTE-240 trial Kudo M.; Lim H.Y.; ANN-LII CHENG; Chao Y.; Yau T.; Ogasawara S.; Kurosaki M.; Morimoto N.; Ohkawa K.; Yamashita T.; Lee K.-H.; Chen E.; Siegel A.B.; Ryoo B.-Y.
臺大學術典藏 2022-02-21T02:04:32Z Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of hepatocellular carcinoma Greten T.F.; Abou-Alfa G.K.; ANN-LII CHENG; Duffy A.G.; El-Khoueiry A.B.; Finn R.S.; Galle P.R.; Goyal L.; He A.R.; Kaseb A.O.; Kelley R.K.; Lencioni R.; Lujambio A.; Mabry Hrones D.; Pinato D.J.; Sangro B.; Troisi R.I.; Wilson Woods A.; Yau T.; Zhu A.X.; Melero I.
國立成功大學 2022 A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors Chan, S.L.;Schuler, M.;Kang, Y.-K.;Yen, C.-J.;Edeline, J.;Choo, S.P.;Lin, C.-C.;Okusaka, T.;Weiss, K.-H.;Macarulla, T.;Cattan, S.;Blanc, J.-F.;Lee, K.-H.;Maur, Maur M.;Pant, S.;Kudo, M.;Assenat, E.;Zhu, A.X.;Yau, T.;Lim, H.Y.;Bruix, J.;Geier, A.;Guill�n-Ponce, C.;Fasolo, A.;Finn, R.S.;Fan, J.;Vogel, A.;Qin, S.;Riester, M.;Katsanou, V.;Chaudhari, M.;Kakizume, T.;Gu, Y.;Porta, D.G.;Myers, A.;Delord, J.-P.
臺大學術典藏 2021-09-01T01:53:56Z Management of colon cancer: Resource-stratified guidelines from the Asian Oncology Summit 2012 Ku G.; Tan I.B.; Yau T.; Boku N.; Laohavinij S.; ANN-LII CHENG; Kang Y.-K.; de Lima Lopes G.
臺大學術典藏 2021-08-31T06:29:37Z Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study ANN-LII CHENG; Cornelio G.; Shen L.; Price T.; Yang T.-S.; Chung I.J.; Dai G.-H.; Lin J.-K.; Sharma A.; Yeh K.-H.; Ma B.; Zaatar A.; Guan Z.; Masood N.; Srimuninnimit V.; Yau T.; Gibbs P.; Wang X.; Doval D.C.; Oh S.-T.; Shim B.Y.; Gorospe C.; Wang H.-M.; Sirachainan E.; Hill A.; Suh K.W.; Beier F.; Chatterjee S.; Lim R.
臺大學術典藏 2021-08-31T06:29:19Z Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial Finn R.S.; Ryoo B.-Y.; Merle P.; Kudo M.; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Knox J.; Daniele B.; Ebbinghaus S.W.; Chen E.; Siegel A.B.; Zhu A.X.; ANN-LII CHENG; KEYnote-240 investigators
臺大學術典藏 2021-08-31T06:29:17Z Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma Kelley R.K.; Mollon P.; Blanc J.-F.; Daniele B.; Yau T.; ANN-LII CHENG; Valcheva V.; Marteau F.; Guerra I.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:16Z Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial Kelley R.K.; Ryoo B.-Y.; Merle P.; Park J.-W.; Bolondi L.; Chan S.L.; Lim H.Y.; Baron A.D.; Parnis F.; Knox J.; Cattan S.; Yau T.; Lougheed J.C.; Milwee S.; El-Khoueiry A.B.; ANN-LII CHENG; Meyer T.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:16Z Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design Kelley R.K.; W Oliver J.; Hazra S.; Benzaghou F.; Yau T.; ANN-LII CHENG; Rimassa L.
臺大學術典藏 2021-08-31T06:29:14Z Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma Sangro B.; Melero I.; Wadhawan S.; Finn R.S.; Abou-Alfa G.K.; ANN-LII CHENG; Yau T.; Furuse J.; Park J.-W.; Boyd Z.; Tang H.T.; Shen Y.; Tschaika M.; Neely J.; El-Khoueiry A.
臺大學術典藏 2021-08-31T06:29:14Z Serum Alpha-fetoprotein Levels and Clinical Outcomes in the Phase III CELESTIAL Study of Cabozantinib versus Placebo in Patients with Advanced Hepatocellular Carcinoma Kelley R.K.; Meyer T.; Rimassa L.; Merle P.; Park J.-W.; Yau T.; Chan S.L.; Blanc J.-F.; Tam V.C.; Tran A.; Dadduzio V.; Markby D.W.; Kaldate R.; ANN-LII CHENG; El-Khoueiry A.B.; Abou-Alfa G.K.
臺大學術典藏 2021-08-31T06:29:13Z Health-related quality-of-life impact of pembrolizumab versus best supportive care in previously systemically treated patients with advanced hepatocellular carcinoma: KEYnote-240 Ryoo B.-Y.; Merle P.; Kulkarni A.S.; ANN-LII CHENG; Bouattour M.; Lim H.Y.; Breder V.; Edeline J.; Chao Y.; Ogasawara S.; Yau T.; Garrido M.; Chan S.L.; Daniele B.; Norquist J.M.; Chen E.; Siegel A.B.; Zhu A.X.; Finn R.S.; Kudo M.
臺大學術典藏 2021-08-11T03:46:38Z A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma Qin S.; Chan S.L.; Sukeepaisarnjaroen W.; Han G.; Choo S.P.; Sriuranpong V.; Pan H.; Yau T.; Guo Y.; Chen M.; Ren Z.; Xu J.; Yen C.-J.; ZHONG-ZHE LIN; Manenti L.; Gu Y.; Sun Y.; Tiedt R.; Hao L.; Song W.; Tanwandee T.
臺大學術典藏 2021-08-11T03:46:35Z First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K.
臺大學術典藏 2021-07-03T03:34:34Z Phase I dose-finding study of pazopanib in hepatocellular carcinoma: Evaluation of early efficacy, pharmacokinetics, and pharmacodynamics Yau T.; PEI-JER CHEN; Chan P.; Curtis C.M.; Murphy P.S.; Suttle A.B.; Gauvin J.; Hodge J.P.; Dar M.M.; Poon R.T.

Showing items 1-25 of 43  (2 Page(s) Totally)
1 2 > >>
View [10|25|50] records per page